180 related articles for article (PubMed ID: 11742873)
1. Arg123-Tyr166 domain of human ApoA-I is critical for HDL-mediated inhibition of macrophage homing and early atherosclerosis in mice.
Holvoet P; Peeters K; Lund-Katz S; Mertens A; Verhamme P; Quarck R; Stengel D; Lox M; Deridder E; Bernar H; Nickel M; Theilmeier G; Ninio E; Phillips MC
Arterioscler Thromb Vasc Biol; 2001 Dec; 21(12):1977-83. PubMed ID: 11742873
[TBL] [Abstract][Full Text] [Related]
2. The Arg123-Tyr166 central domain of human ApoAI is critical for lecithin:cholesterol acyltransferase-induced hyperalphalipoproteinemia and HDL remodeling in transgenic mice.
Holvoet P; De Geest B; Van Linthout S; Lox M; Danloy S; Raes K; Collen D
Arterioscler Thromb Vasc Biol; 2000 Feb; 20(2):459-66. PubMed ID: 10669644
[TBL] [Abstract][Full Text] [Related]
3. Role of the Arg123-Tyr166 paired helix of apolipoprotein A-I in lecithin:cholesterol acyltransferase activation.
Dhoest A; Zhao Z; De Geest B; Deridder E; Sillen A; Engelborghs Y; Collen D; Holvoet P
J Biol Chem; 1997 Jun; 272(25):15967-72. PubMed ID: 9188498
[TBL] [Abstract][Full Text] [Related]
4. Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice: LCAT gene transfer decreases atherosclerosis.
Mertens A; Verhamme P; Bielicki JK; Phillips MC; Quarck R; Verreth W; Stengel D; Ninio E; Navab M; Mackness B; Mackness M; Holvoet P
Circulation; 2003 Apr; 107(12):1640-6. PubMed ID: 12668499
[TBL] [Abstract][Full Text] [Related]
5. Natural human apoA-I mutations L141RPisa and L159RFIN alter HDL structure and functionality and promote atherosclerosis development in mice.
Tiniakou I; Kanaki Z; Georgopoulos S; Chroni A; Van Eck M; Fotakis P; Zannis VI; Kardassis D
Atherosclerosis; 2015 Nov; 243(1):77-85. PubMed ID: 26363436
[TBL] [Abstract][Full Text] [Related]
6. Mast cell chymase degrades apoE and apoA-II in apoA-I-knockout mouse plasma and reduces its ability to promote cellular cholesterol efflux.
Lee M; Calabresi L; Chiesa G; Franceschini G; Kovanen PT
Arterioscler Thromb Vasc Biol; 2002 Sep; 22(9):1475-81. PubMed ID: 12231569
[TBL] [Abstract][Full Text] [Related]
7. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential.
Ribas V; Sánchez-Quesada JL; Antón R; Camacho M; Julve J; Escolà-Gil JC; Vila L; Ordóñez-Llanos J; Blanco-Vaca F
Circ Res; 2004 Oct; 95(8):789-97. PubMed ID: 15388641
[TBL] [Abstract][Full Text] [Related]
8. Influence of macrophage-derived apolipoprotein E on plasma lipoprotein distribution of apolipoprotein A-I in apolipoprotein E-deficient mice.
Spangenberg J; Curtiss LK
Biochim Biophys Acta; 1997 Nov; 1349(2):109-21. PubMed ID: 9421184
[TBL] [Abstract][Full Text] [Related]
9. Apolipoprotein A-I protection against atherosclerosis is dependent on genetic background.
Sontag TJ; Krishack PA; Lukens JR; Bhanvadia CV; Getz GS; Reardon CA
Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):262-9. PubMed ID: 24334873
[TBL] [Abstract][Full Text] [Related]
10. In vivo interactions of apoA-II, apoA-I, and hepatic lipase contributing to HDL structure and antiatherogenic functions.
Hedrick CC; Castellani LW; Wong H; Lusis AJ
J Lipid Res; 2001 Apr; 42(4):563-70. PubMed ID: 11290828
[TBL] [Abstract][Full Text] [Related]
11. Short-term feeding of atherogenic diet to mice results in reduction of HDL and paraoxonase that may be mediated by an immune mechanism.
Hedrick CC; Hassan K; Hough GP; Yoo JH; Simzar S; Quinto CR; Kim SM; Dooley A; Langi S; Hama SY; Navab M; Witztum JL; Fogelman AM
Arterioscler Thromb Vasc Biol; 2000 Aug; 20(8):1946-52. PubMed ID: 10938016
[TBL] [Abstract][Full Text] [Related]
12. Substitution of the carboxyl-terminal domain of apo AI with apo AII sequences restores the potential of HDL to reduce the progression of atherosclerosis in apo E knockout mice.
Holvoet P; Danloy S; Deridder E; Lox M; Bernar H; Dhoest A; Collen D
J Clin Invest; 1998 Jul; 102(2):379-85. PubMed ID: 9664079
[TBL] [Abstract][Full Text] [Related]
13. Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation.
Moore RE; Navab M; Millar JS; Zimetti F; Hama S; Rothblat GH; Rader DJ
Circ Res; 2005 Oct; 97(8):763-71. PubMed ID: 16151025
[TBL] [Abstract][Full Text] [Related]
14. Long-term stable expression of human apolipoprotein A-I mediated by helper-dependent adenovirus gene transfer inhibits atherosclerosis progression and remodels atherosclerotic plaques in a mouse model of familial hypercholesterolemia.
Belalcazar LM; Merched A; Carr B; Oka K; Chen KH; Pastore L; Beaudet A; Chan L
Circulation; 2003 Jun; 107(21):2726-32. PubMed ID: 12742997
[TBL] [Abstract][Full Text] [Related]
15. Dysfunctional HDL containing L159R ApoA-I leads to exacerbation of atherosclerosis in hyperlipidemic mice.
Sorci-Thomas MG; Zabalawi M; Bharadwaj MS; Wilhelm AJ; Owen JS; Asztalos BF; Bhat S; Thomas MJ
Biochim Biophys Acta; 2012 Mar; 1821(3):502-12. PubMed ID: 21944998
[TBL] [Abstract][Full Text] [Related]
16. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice.
Navab M; Anantharamaiah GM; Reddy ST; Hama S; Hough G; Grijalva VR; Wagner AC; Frank JS; Datta G; Garber D; Fogelman AM
Circulation; 2004 Jun; 109(25):3215-20. PubMed ID: 15197147
[TBL] [Abstract][Full Text] [Related]
17. High levels of human apolipoprotein A-I and high density lipoproteins in transgenic mice do not enhance efflux of cholesterol from a depot of injected lipoproteins. Relevance to regression of atherosclerosis?
Stein O; Dabach Y; Hollander G; Ben-Naim M; Halperin G; Stein Y
Atherosclerosis; 1999 Jun; 144(2):367-74. PubMed ID: 10407497
[TBL] [Abstract][Full Text] [Related]
18. Hyperhomocysteinemia decreases circulating high-density lipoprotein by inhibiting apolipoprotein A-I Protein synthesis and enhancing HDL cholesterol clearance.
Liao D; Tan H; Hui R; Li Z; Jiang X; Gaubatz J; Yang F; Durante W; Chan L; Schafer AI; Pownall HJ; Yang X; Wang H
Circ Res; 2006 Sep; 99(6):598-606. PubMed ID: 16931800
[TBL] [Abstract][Full Text] [Related]
19. Retrovirus-mediated expression of apolipoprotein A-I in the macrophage protects against atherosclerosis in vivo.
Ishiguro H; Yoshida H; Major AS; Zhu T; Babaev VR; Linton MF; Fazio S
J Biol Chem; 2001 Sep; 276(39):36742-8. PubMed ID: 11477092
[TBL] [Abstract][Full Text] [Related]
20. Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein[a] in transgenic mice.
Liu AC; Lawn RM; Verstuyft JG; Rubin EM
J Lipid Res; 1994 Dec; 35(12):2263-7. PubMed ID: 7897323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
